The Clinical Applications of New DNA Diagnostic Technology on the Management of Cancer Patients
- Janet D. Rowley, MD;
- Jon C. Aster, MD;
- Jeffrey Sklar, MD, PhD
- From the Departments of Medicine and Molecular Genetics and Cell Biology, University of Chicago (Ill) Medical Center (Dr Rowley), and Department of Pathology, Brigham and Women's Hospital, Boston, Mass (Drs Aster and Sklar). Dr Rowley represents the participants in the Panel for a Research Briefing, Institute of Medicine, Washington, DC.
Since this article does not have an abstract, we have provided the first 150 words of the full text.
Excerpt
THIS ARTICLE presents a summary of the results of investigations to detect the various genetic changes that have been identified in malignant cells, concentrating on those malignant diseases that have been well characterized genetically. Various techniques are reviewed elsewhere.1 The correlation of the genetic changes with features that aid in the distinction of different tumors or that have prognostic significance will be emphasized. The explosive growth in this area of clinical investigation causes any review of this sort to become out of date rapidly. Nonetheless, these examples are important illustrations of the future of medical practice. Detailed summaries of chromosome abnormalities in cancer have been described previously.2,3 The article is divided into two major parts, hematologic malignant diseases and solid tumors. At present, we know much more about the hematologic disorders, especially leukemia and lymphoma.4 This is rapidly changing as many laboratories are actively investigating the genetic
Footnotes
-
A complete list of participants in the Panel for a Research Briefing appears at the end of this article.
-
Reprint requests to Department of Medicine, University of Chicago Medical Center, 5841 S Maryland Ave, MC 2115, Chicago, IL 60637-1470 (Dr Rowley).
